NLS Pharmaceutics Prices $1.75M Direct Offering
Ticker: NCEL · Form: 6-K · Filed: Mar 21, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.25, $1,750,000, $100,000, $0.3125, $1.75 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: direct-offering, financing, pharmaceuticals
TL;DR
NLS Pharma raising $1.75M via direct offering at $0.25/share, closing March 22.
AI Summary
On March 20, 2024, NLS Pharmaceutics Ltd. announced a registered direct offering to issue 7,000,000 common shares at $0.25 per share. The offering is expected to close around March 22, 2024, subject to standard closing conditions.
Why It Matters
This registered direct offering provides NLS Pharmaceutics with capital, potentially to fund its ongoing operations and development of its pharmaceutical products.
Risk Assessment
Risk Level: medium — Direct offerings can dilute existing shareholders and may indicate a need for immediate capital, suggesting potential financial pressures.
Key Numbers
- $1.75M — Gross Proceeds (Calculated from 7,000,000 shares at $0.25 per share.)
- 7,000,000 — Shares Offered (Number of common shares being issued in the direct offering.)
- $0.25 — Price Per Share (The price at which each common share is being offered.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Issuer of shares
- March 20, 2024 (date) — Date of purchase agreement
- 7,000,000 (dollar_amount) — Number of common shares to be issued
- $0.25 (dollar_amount) — Purchase price per share
- March 22, 2024 (date) — Expected closing date of the offering
FAQ
What is the total amount NLS Pharmaceutics expects to raise from this offering?
NLS Pharmaceutics expects to raise approximately $1.75 million from the sale of 7,000,000 common shares at $0.25 per share.
When is the registered direct offering expected to close?
The offering is expected to close on or about March 22, 2024.
What type of securities are being offered?
The company is offering common shares, par value CHF 0.02 per share.
What is the par value of the common shares being offered?
The common shares have a par value of CHF 0.02 per share.
Are there any specific conditions mentioned for the closing of the offering?
Yes, the closing is subject to the satisfaction of customary closing conditions and requirements.
Filing Stats: 1,245 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2024-03-21 17:14:29
Key Financial Figures
- $0.25 — e Common Shares, at a purchase price of $0.25 per share. The offering is expected to
- $1,750,000 — ult in gross proceeds to the Company of $1,750,000. The Company intends to use the net pro
- $100,000 — the securities sold in the offering and $100,000 in accountable expenses. In addition, t
- $0.3125 — ch will have an exercise price equal to $0.3125 per share, and will be immediately exer
- $1.75 Million — led: “NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering” 3
Filing Documents
- ea0202255-6k_nlspharma.htm (6-K) — 20KB
- ea020225501ex4-1_nlspharma.htm (EX-4.1) — 86KB
- ea020225501ex4-2_nlspharma.htm (EX-4.2) — 87KB
- ea020225501ex5-1_nlspharma.htm (EX-5.1) — 26KB
- ea020225501ex10-1_nlspharma.htm (EX-10.1) — 257KB
- ea020225501ex99-1_nlspharma.htm (EX-99.1) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-024841.txt ( ) — 494KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: March 21, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 4